The US Federal Trade Commission has reportedly filed an amicus brief urging an appeals court to reverse an earlier dismissal of a pharmaceutical pay-for-delay lawsuit.
The FTC filed the brief in the US Court of Appeals for the Third Circuit, asking it to reverse the dismissal of Lamictal Direct Purchaser Antitrust Litigation, initially tossed after a district court found that a brand-name pharmaceutical’s agreement with its generic counterpart cannot be deemed a violation of antitrust law under the Supreme Court’s decision in FTC v. Actavis, Inc. because the agreement in question did not involve “cash.”
But according to the FTC, the District Court was erroneous in its dismissal because the pay-for-delay agreement made between the brand-name and generic makers of Lamictal issues the same antitrust issues as Actavis based on the regulator’s empirical study of the competitive effects of such decisions.
A pay-for-delay agreement involves a brand-name drug maker paying its generic competitor to delay the release of its cheaper drug.
Full content: IP Watchdog
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI